A multi-center interventional study to assess pharmacokinetics, effectiveness, and tolerability of prolonged-release tacrolimus after pediatric kidney transplantation: study protocol for a prospective, open-label, randomized, two-phase, two-sequence, single dose, crossover, phase III b trial.

Karaterzi S, Tönshoff B, Ahlenstiel-Grunow T, Baghai M, Beck B, Büscher A, Eifler L, Giese T, Lezius S, Müller C, Oh J, Zapf A, Weber LT, Pape L

Frontiers in nephrology, 2024

doi:10.3389/fneph.2024.1331510.

High-throughput anaerobic screening for identifying compounds acting against gut bacteria in monocultures or communities.

Müller P, de la Cuesta-Zuluaga J, Kuhn M, Baghai Arassi M, Treis T, Blasche S, Zimmermann M, Bork P, Patil KR, Typas A, Garcia-Santamarina S, Maier L

Nature protocols, 2023

doi:10.1038/s41596-023-00926-4.

Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk.

Baghai Arassi M, Gauche L, Schmidt J, Höcker B, Rieger S, Süsal C, Tönshoff B, Fichtner A

Pediatric nephrology (Berlin, Germany), 2022

doi:10.1007/s00467-022-05426-3.

The gut microbiome in solid organ transplantation.

Baghai Arassi M, Zeller G, Karcher N, Zimmermann M, Toenshoff B

Pediatric transplantation, 2020

doi:10.1111/petr.13866.